SINOVAC Biotech and BioMap Announce Strategic Collaboration to Advance AI-Driven Innovative Drug Discovery

‌On March 21, 2025, BioMap (Beijing) Intelligent Technology Co., Ltd. (hereinafter referred to as "BioMap")BioMap announced a strategic partnership with Kexing Biopharm Co., Ltd. (referred to as "Kexing Biopharm," stock code: 688136.SH). The collaboration will focus on the deep integration of artificial intelligence (AI) technology and innovative drug research and development.Systematic collaboration focuses on the entire process of large-molecule drug development in fields such as oncology and autoimmune diseases, accelerating the development of more groundbreaking therapeutic drugs.

‌Embrace AI, Technical Advantages Accelerate R&D

Kexing Biopharm is an innovative biopharmaceutical company mainly engaged in the integrated research, production, and sales of large-molecule biological drugs. It focuses on therapeutic areas such as antiviral, anti-tumor, and autoimmune treatments, while building cutting-edge biotechnology platforms for novel proteins, novel antibodies, and nucleic acid drugs. Since 2023, the company has started combining innovative drug research with AI technology, gradually constructing a highly intelligent R&D innovation system in areas such as target discovery, molecular design, drug-likeness optimization, and preclinical studies, focusing on unmet clinical needs and opening up a new perspective for "first-in-class" drug development.

Kexing Biopharm's deep accumulation in the industrialization of biopharmaceuticals will complement and synergize with BioMap's AI technology advantages. Especially in the research and development of antibody drugs, the BioMap AI platform can accurately predict antibody molecular design.Assist in designing candidate molecules with high stability and low immunogenicity; Kexing Biopharm has mature drugability evaluation technology and reliable capabilities.The construction of cell lines, process development, and scale-up production capabilities will accelerate the commercialization of such molecules. The strong collaboration between the two companies has the potential to break through the limitations of single-step optimization in AI drug discovery, redefine the logic of technological innovation through full-chain empowerment, and set new standards for key metrics such as target discovery success rates and preclinical development costs.

AI Empowerment: Reshaping the Entire Drug R&D Chain

BioMap is a pioneer in global life science foundational large models. Using a cross-modal biological language model with 210 billion parameters, it decodes the underlying principles of genomes, proteins, cells, and biological systems, building high-quality AI task models for life sciences with smaller data and cost consumption. Currently, BioMap has achieved State-of-the-Art (SOTA) performance in over 200 task models across drug discovery, biomanufacturing, healthcare, and other fields, serving more than 400 users worldwide.Empower users inBreakthrough achievements have been made in AI-driven protein design, AI target discovery, and AI enzyme design. BioMapFounded by Baidu's founder Robin Li and former Baidu VenturesCo-founded by CEO Liu Wei, with a core team comprising former senior executives from the industry, such as the ex-Global Vice President of Novo Nordisk and the ex-Global Vice President of SAP. Research and development centers have been established in Silicon Valley, Beijing, Suzhou, and Hong Kong, with nearly 200 million US dollars in funding secured.

In terms of target discovery and molecular design, combining the latest global scientific research literature and publicly available informationClinical trial data and patent information, BioMap's AI generative discovery system can predict the correlation between targets and disease mechanisms through deep learning, from massive genomics, proteomicsIdentifying potential therapeutic targets from the data. Generating tens of thousands of candidate molecules quickly based on target structures, simulating drug-target binding modes, predicting molecular activity, selectivity, and metabolic properties, avoiding safety risks in drug development, greatly improving efficiency compared to traditional manual methods, shortening the early drug design cycle from years to months, and reducing preclinical experimental costs.

At the signing ceremony, Yanqing Zhao, General Manager of Kexing Biopharm, stated, "With BioMap's powerful large foundational model in life sciences, Kexing Biopharm will prioritize the application of AI technology in high-potential R&D pipelines such as oncology and autoimmune drugs. We believe that the collaboration between both parties will become a valuable case of biotechnology and AI integration."

BioMap President Deng Yongfu expressed anticipation for the collaboration between both parties, "Kexing Biopharm is a pharmaceutical enterprise with deep biotechnological accumulation, and BioMap has been continuously making breakthroughs in AI-driven drug research and development. We hope to optimize the drug development pathway through AI technology and help more innovative projects from Kexing Biopharm enter the clinical research stage."

This strategic cooperation between the two parties, ranging from technology empowerment to ecological co-construction, from efficiency enhancement to scientific discovery, will provide a benchmark case of "AI + Industry" for China's biopharmaceuticals industry through the synergistic innovation of BioMap and Kexing Biopharm, accelerating the global innovative drug R&D into an intelligence-driven era.

In the future, BioMap will continue to explore the technological innovation and application of AI life science fundamental large models in innovative drug research and development, promote cooperation with more academic institutions, clinical institutions, and leading pharmaceutical companies, and jointly contribute to the development of China's innovative drugs.